Overview

We held 1st China Pharma IP Summit 2016 on 17-18, November last year and confirmed more than 190 attendees from government agencies, in-house IP counsel, IP law firms, agencies and solution providers. The development of pharmaceutical industry heavily relies on their IP strategies, and this year pharmaceutical IP protection in China is drawing more attentions than before. Firstly, on 12th May 2017, the China Food and Drug Administration issued a proposal ( called 2017 Policy Notice No.55), which proposes to establish the patent linkage and amend the regulatory data protection regime. In the Notice No.55, it indicates the procedures of patent linkage and changes of regulatory data protection. Secondly, China is studying the drug patent extension reform, and the result may come out within this year. Additionally, the SIPO is amending PATENT LAW OF THE PEOPLE'S REPUBLIC OF CHINA and the new amendments to SIPO's Guidelines for Patent Examination has been effective since 1st April, 2017.

Based on above we will launch 2nd China Pharma IP Summit 2017 on 7th -8th December this year in Shanghai, and continue to provide a networking platform for industry peers.

Through the event, you can:

1. Follow updated policies in China, including patent linkage, regulatory data protection, patent extension reform, and the changes of Patent Law and Guidelines for Patent Examination.

2. Understand the latest examination standards and litigation proceedings in US and Europe

3. Learn excellent IP management cases

4. Meet you client fact to face and interacts with industry peers

The participants are mainly from pharma companies, biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

Thanks again for your attention and looking forward to your participation!

Agenda:

DAY 1 Morning

0730

Registration Open

0840

Opening Remark

Day1 Chairman: Tony Chen, Partner, Jones Day

0850

Managing Global IP Strategy & Team--Practical Insights

John D. Conway, Senior Vice President and Global Head of Intellectual Property, Sanofi

0925

505(b)(2) NDAs v. ANDAs: Case Studies and Implications for Patent Portfolio Development and US Litigation

TheLatest Developments of Patenting Pharmaceutical and Biotechnological Inventions at the EPO

The speaker will build up on his last year’s presentation and update more specifically on new case law and practice as regards patentability requirements for pharmaceuticals and biotechnological inventions, including the recent changes to the implementing regulations in respect of plant patenting. He will also update on other EPO developments such as the new opposition practice, IP5 developments (global dossier, extension of validation states and PPH)